Glioblastoma (GBM) is the most common and fatal primary central nervous system
malignancy in adults with a median survival of less than 15 months. Surgery, radiation, and …

Glioblastoma is the most common primary brain tumor and has a dismal prognosis. The
development of central necrosis represents a tipping point in the evolution of these tumors …

Purpose: Oncolytic herpes simplex virus-1 (oHSV) infection of brain tumors activates
NOTCH, however the consequences of NOTCH on oHSV-induced immunotherapy is largely …

High mobility group box 1 (HMGB1) is an extremely versatile protein that is located
predominantly in the nucleus of quiescent eukaryotic cells, where it is critically involved in …

Introduction To overcome the challenge of treating malignant brain tumors, oncolytic viruses
(OVs) represent an innovative therapeutic approach, featuring unique mechanisms of action …

Surgical removal of tumors remains a front-line therapy for many types of cancer. However,
this treatment often fails to eradicate disease due to either recurrence of the original tumor or …

Inflammatory responses, characterized by the overproduction of numerous proinflammatory
mediators by immune cells, is essential to protect the host against invading pathogens …

Glioblastoma (GBM) is a lethal primary malignant brain tumor with no current effective
treatments. The recent emergence of immuno-virotherapy and FDA approval of T-VEC have …

Oncolytic herpes simplex virus (oHSV) is a highly promising treatment for solid tumors.
Intense research and development efforts have led to first-in-class approval for an oHSV for …

Oncolytic virotherapy has produced promising yet limited results in preclinical and clinical
studies. Besides direct oncolytic activity, a significant therapeutic mechanism of oncolytic …